Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 2
2003 4
2004 1
2006 1
2007 3
2009 5
2010 4
2011 2
2012 2
2013 3
2014 3
2015 3
2016 2
2017 5
2018 3
2019 6
2020 10
2021 9
2022 14
2023 15
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - relationship with the reason for withdrawal from the previous treatment.
Ørnbjerg LM, Brahe CH, Linde L, Jacobsson L, Nissen MJ, Kristianslund EK, Santos MJ, Nordström D, Rotar Z, Gudbjornsson B, Onen F, Codreanu C, Lindström U, Möller B, Kvien TK, Barcelos A, Eklund KK, Tomšič M, Love TJ, Can G, Ionescu R, Loft AG, Mann H, Pavelka K, van de Sande M, van der Horst-Bruinsma IE, Suarez MP, Sánchez-Piedra C, Macfarlane GJ, Iannone F, Michelsen B, Hyldstrup LH, Krogh NS, Østergaard M, Hetland ML. Ørnbjerg LM, et al. Among authors: moller b. Joint Bone Spine. 2024 Apr 4;91(4):105729. doi: 10.1016/j.jbspin.2024.105729. Online ahead of print. Joint Bone Spine. 2024. PMID: 38582359
Validation of SPARCC MRI-RETIC e-tools for increasing scoring proficiency of MRI sacroiliac joint lesions in axial spondyloarthritis.
Maksymowych W, Hadsbjerg AEFEF, Østergaard M, Micheroli R, Pedersen SJ, Ciurea A, Vladimirova N, Nissen MS, Bubova K, Wichuk S, de Hooge M, Mathew AJ, Pintaric K, Gregová M, Snoj Z, Wetterslev M, Gorican K, Möller B, Eshed I, Paschke J, Lambert RG. Maksymowych W, et al. Among authors: moller b. RMD Open. 2024 Feb 13;10(1):e003923. doi: 10.1136/rmdopen-2023-003923. RMD Open. 2024. PMID: 38351052 Free PMC article. Clinical Trial.
Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care.
Ørnbjerg LM, Rugbjerg K, Georgiadis S, Rasmussen SH, Jacobsson L, Loft AG, Iannone F, Fagerli KM, Vencovsky J, Santos MJ, Möller B, Pombo-Suarez M, Rotar Z, Gudbjornsson B, Cefle A, Eklund K, Codreanu C, Jones G, van der Sande M, Wallman JK, Sebastiani M, Michelsen B, Závada J, Nissen MJ, Sanchez-Piedra C, Tomšič M, Love TJ, Relas H, Mogosan C, Hetland ML, Østergaard M. Ørnbjerg LM, et al. Among authors: moller b. J Rheumatol. 2024 Apr 1;51(4):378-389. doi: 10.3899/jrheum.2023-0764. J Rheumatol. 2024. PMID: 38224992 Free article.
Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry.
Ciurea A, Götschi A, Bräm R, Bürki K, Exer P, Andor M, Nissen MJ, Möller B, Hügle T, Rubbert-Roth A, Kyburz D, Distler O, Scherer A, Micheroli R. Ciurea A, et al. Among authors: moller b. RMD Open. 2023 Dec 1;9(4):e003455. doi: 10.1136/rmdopen-2023-003455. RMD Open. 2023. PMID: 38053462 Free PMC article.
Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network.
Hellamand P, van de Sande MGH, Ørnbjerg LM, Klausch T, Eklund KK, Relas H, Santos MJ, Vieira-Sousa E, Loft AG, Glintborg B, Østergaard M, Lindström U, Wallman JK, Michelsen B, Fagerli KM, Castrejón I, Gudbjornsson B, Love TJ, Vencovský J, Nekvindová L, Rotar Ž, Tomšič M, Díaz-González F, Kenar G, Tuğsal HY, Iannone F, Ramonda R, Codreanu C, Mogosan C, Nissen MJ, Möller B, Hetland ML, van der Horst-Bruinsma IE. Hellamand P, et al. Among authors: moller b. Arthritis Rheumatol. 2024 Apr;76(4):587-598. doi: 10.1002/art.42758. Epub 2024 Feb 25. Arthritis Rheumatol. 2024. PMID: 37975166
Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care.
Riek M, Scherer A, Möller B, Ciurea A, von Mühlenen I, Gabay C, Kyburz D, Brulhart L, von Kempis J, Mueller RB, Hasler P, Strahm T, von Känel S, Zufferey P, Dudler J, Finckh A. Riek M, et al. Among authors: moller b. Sci Rep. 2023 Oct 18;13(1):17776. doi: 10.1038/s41598-023-44841-w. Sci Rep. 2023. PMID: 37853058 Free PMC article.
Biological disease-modifying anti-rheumatic drugs are equally effective in psoriatic arthritis patients with low and high joint counts.
Möller B, Scholz GA, Amsler J, Ciurea A, Micheroli R, Nissen MJ, Papagiannoulis E, Blapp C, Scherer A, Yawalkar N; Swiss Clinical Quality Management (SCQM) physicians, researchers and patients. Möller B, et al. Rheumatology (Oxford). 2023 Sep 7:kead455. doi: 10.1093/rheumatology/kead455. Online ahead of print. Rheumatology (Oxford). 2023. PMID: 37676822
91 results